Claims

1. Use of niraparib or a salt thereof in the manufacture of a medicament for the treatment of prostate cancer wherein the medicament is to be administered in a safe and effective amount to a human in need thereof and wherein the human is carrying at least one DNA repair anomaly selected from the group consisting of BRCA-1 and BRCA-2.

2. The use of claim 1, wherein the prostate cancer is a castration-resistant prostate cancer or metastatic castration-resistant prostate cancer.

3. The use of claim 2, wherein the prostate cancer is antiandrogen resistant.

4. The use of any one of the preceding claims, wherein niraparib is to be administered in an amount of from 30 mg/day to 400 mg/day.

5. The use of claim 4, wherein the amount of niraparib to be administered is 300 mg/day.

6. The use of claim 5, wherein niraparib is to be administered as once daily oral administration in three 100 mg oral dosage forms.